GleamWall
中文EN

TRFA TRAFALGAR INTERNATIONAL, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1695473 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY221.7%
TTM EPS YoY274.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA6,559.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets11,026.1%
Debt / equity—
Current ratio0.01x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.05x
Accruals ratio6,862.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
Operating income-$183,005-$156,276
Pretax income-$331,612-$179,041
Net income-$331,612-$179,041
EPS (basic)0.000.00
EPS (diluted)0.000.00
Weighted avg. shares (diluted)824,984536,622
Balance sheet
Cash & equivalents$815$57,368
Current assets$815$57,368
Total assets$815$57,785
Current liabilities$742,464$898,058
Total liabilities$742,464$898,058
Shareholders' equity-$741,649-$840,273
Shares outstanding944,935536,622
Cash flow statement
Operating cash flow-$60,153-$109,491
Financing cash flow$3,600—
Stock-based compensation$1,800—

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.